Skip to main content
. 2019 May 17;36(7):1786–1811. doi: 10.1007/s12325-019-00985-8

Table 2.

Summary data for the 11 patients

Parameter Age Baseline LDL-C, mg/dL Nadir LDL-C, mg/dL Percentage reduction in LDL-C from baseline to nadir, % Lomitapide dose, mg/day Lomitapide exposure, months
Mean 11.6 422.7 192.2 56.7 25.0 20.0
Median 12.0 325.5 98.0 61.2 20.0 18.2
SD 3.8 245.4 163.2 21.7 13.8 9.5

LDL-C, low-density lipoprotein cholesterol; SD, standard deviation